569 related articles for article (PubMed ID: 25380051)
1. Rationale and study design of the RESERVOIR trial: a randomized trial comparing reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus.
Romaguera R; Brugaletta S; Gomez-Lara J; Pinar E; Jiménez-Quevedo P; Gracida M; Roura G; Ferreiro JL; Teruel L; Gómez-Hospital JA; Montanya E; Alfonso F; Valgimigli M; Sabate M; Cequier A
Catheter Cardiovasc Interv; 2015 Mar; 85(4):E116-22. PubMed ID: 25380051
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus: The RESERVOIR Clinical Trial.
Romaguera R; Gómez-Hospital JA; Gomez-Lara J; Brugaletta S; Pinar E; Jiménez-Quevedo P; Gracida M; Roura G; Ferreiro JL; Teruel L; Montanya E; Fernandez-Ortiz A; Alfonso F; Valgimigli M; Sabate M; Cequier A
JACC Cardiovasc Interv; 2016 Jan; 9(1):42-50. PubMed ID: 26762910
[TBL] [Abstract][Full Text] [Related]
3. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schömig A; Kastrati A
Catheter Cardiovasc Interv; 2013 Nov; 82(6):E769-76. PubMed ID: 23754254
[TBL] [Abstract][Full Text] [Related]
4. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
5. Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial.
Teeuwen K; van der Schaaf RJ; Adriaenssens T; Koolen JJ; Smits PC; Henriques JP; Vermeersch PH; Tjon Joe Gin RM; Schölzel BE; Kelder JC; Tijssen JG; Agostoni P; Suttorp MJ
JACC Cardiovasc Interv; 2017 Jan; 10(2):133-143. PubMed ID: 28104206
[TBL] [Abstract][Full Text] [Related]
6. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).
Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO
Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050
[TBL] [Abstract][Full Text] [Related]
7. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
8. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
[TBL] [Abstract][Full Text] [Related]
9. PLATINUM China: a prospective, randomized investigation of the platinum chromium everolimus-eluting stent in de novo coronary artery lesions.
Gao R; Han Y; Yang Y; Zhang J; Hou Y; Wang H; Li H; Fang Q; Yu B; Xu B; Allocco DJ; Dawkins KD
Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():716-23. PubMed ID: 25631909
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial.
Franzone A; Pilgrim T; Heg D; Roffi M; Tüller D; Vuilliomenet A; Muller O; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Räber L; Stortecky S; Wenaweser P; Jüni P; Windecker S
Circ Cardiovasc Interv; 2015 Jun; 8(6):. PubMed ID: 26043895
[TBL] [Abstract][Full Text] [Related]
11. Very early neointimal coverage of new biodegradable polymer drug-eluting stent compared with durable polymer everolimus-eluting stent evaluated by optical frequency domain imaging.
Kobayashi N; Ito Y; Yamawaki M; Araki M; Sakai T; Sakamoto Y; Mori S; Tsutsumi M; Nauchi M; Honda Y; Tokuda T; Makino K; Shirai S; Hirano K
Int J Cardiovasc Imaging; 2018 Apr; 34(4):515-522. PubMed ID: 29159531
[TBL] [Abstract][Full Text] [Related]
12. A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study.
Teeuwen K; Adriaenssens T; Van den Branden BJ; Henriques JP; Van der Schaaf RJ; Koolen JJ; Vermeersch PH; Bosschaert MA; Tijssen JG; Suttorp MJ
Trials; 2012 Dec; 13():240. PubMed ID: 23241457
[TBL] [Abstract][Full Text] [Related]
13. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
15. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial.
Windecker S; Haude M; Neumann FJ; Stangl K; Witzenbichler B; Slagboom T; Sabaté M; Goicolea J; Barragan P; Cook S; Piot C; Richardt G; Merkely B; Schneider H; Bilger J; Erne P; Waksman R; Zaugg S; Jüni P; Lefèvre T
Circ Cardiovasc Interv; 2015 Feb; 8(2):e001441. PubMed ID: 25634905
[TBL] [Abstract][Full Text] [Related]
16. First-in-man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo coronary lesions: clinical, Angiographic, and OCT outcomes of CREDIT-1.
Wang G; Sun Z; Jin Q; Xu K; Li Y; Wang X; Ma Y; Liu H; Zhao X; Wang B; Deng J; Guan S; Ge M; Wang X; Xu B; Han Y
Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():744-51. PubMed ID: 25630447
[TBL] [Abstract][Full Text] [Related]
17. Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial).
Stiermaier T; Heinz A; Schloma D; Kleinertz K; Dänschel W; Erbs S; Linke A; Boudriot E; Lauer B; Schuler G; Thiele H; Desch S
Catheter Cardiovasc Interv; 2014 Feb; 83(3):418-24. PubMed ID: 23873579
[TBL] [Abstract][Full Text] [Related]
18. Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).
Sen H; Lam MK; Löwik MM; Danse PW; Jessurun GA; van Houwelingen KG; Anthonio RL; Tjon Joe Gin RM; Hautvast RW; Louwerenburg JH; de Man FH; Stoel MG; van der Heijden LC; Linssen GC; IJzerman MJ; Tandjung K; Doggen CJ; von Birgelen C
JACC Cardiovasc Interv; 2015 Jun; 8(7):889-99. PubMed ID: 26003019
[TBL] [Abstract][Full Text] [Related]
19. Intimal hyperplasia and vascular remodeling after everolimus-eluting and sirolimus-eluting stent implantation in diabetic patients: the randomized Diabetes and Drug-Eluting Stent (DiabeDES) IV Intravascular Ultrasound trial.
Antonsen L; Maeng M; Thayssen P; Christiansen EH; Hansen KN; Kaltoft A; Hansen HS; Thuesen L; Lassen JF; Jensen LO
Catheter Cardiovasc Interv; 2014 May; 83(6):864-72. PubMed ID: 23996918
[TBL] [Abstract][Full Text] [Related]
20. Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent.
Rozemeijer R; Stein M; Voskuil M; van den Bor R; Frambach P; Pereira B; Koudstaal S; Leenders GE; Timmers L; Rittersma SZ; Kraaijeveld AO; Agostoni P; Roes KC; Doevendans PA; Stella PR;
Circulation; 2019 Jan; 139(1):67-77. PubMed ID: 30586704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
